Pediatric vasculitis: Advances in treatment

Current Opinion in Rheumatology

Volumn 27, Issue 5, 2015, Pages 493-499

  Morishita, Kimberly ^a   Brown, Kelly ^a   Cabral, David ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

ANCA associated vasculitis; Pediatrics; Polyarteritis nodosa; Systemic vasculitis; Takayasu arteritis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; LEFLUNOMIDE; METHOTREXATE; MITOMYCIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ANCA ASSOCIATED VASCULITIS; AORTA ARCH SYNDROME; BIOLOGICAL THERAPY; CHILDHOOD DISEASE; CHRONIC DISEASE; CLINICAL EFFECTIVENESS; CORTICOSTEROID THERAPY; EVIDENCE BASED PRACTICE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAINTENANCE THERAPY; OUTCOME ASSESSMENT; PEDIATRIC SURGERY; POLYARTERITIS NODOSA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SUBGLOTTIC STENOSIS; SYSTEMIC VASCULITIS; TRACHEA STENOSIS; CHILD; TAKAYASU ARTERITIS; TREATMENT OUTCOME;

CHILD; CHRONIC DISEASE; HUMANS; SYSTEMIC VASCULITIS; TAKAYASU ARTERITIS; TREATMENT OUTCOME;

EID: 84942603013     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000203     Document Type: Review

References (78)

1. Hunder GG, Arend WP, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum 1990; 33:1065-1067.
2. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37:187-192. 3.
3. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1-11. This revised international nomenclature for vasculitis additionally provides consensus recommendations on preferred abbreviations and disease definitions that have incorporated new knowledge and reflect an improved understanding of these diseases since the 1994 recommendations. They provid ed a framework for the classification of vasculitis, which establishes a framework for stratified therapies and future clinical trials.
4. Ozen S, Pistorio A, Iusan SM, et al. EULAR/PRINTO/PRES criteria for Henoch-Schonlei n purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II. Final classification criteria. Ann Rheum Dis 2010; 69:798-806.
5. Mukh tyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68:310-317.
6. Adu D, Pall A, Luqmani RA, et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM 1997; 90:401-409.
7. Rihova Z, Jancova E, Merta M, et al. Daily oral versus pulse intravenous cyclophosphamide in the therapy of ANCA-Associated vasculitis: preliminary single center experience. Prague Med Rep 2004; 105:64-68.
8. de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibodyassociated vasculitis: a randomized trial. Ann Intern Med 2009; 150:670-680.
9. Jayne DR, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18:2180-2188.
10. Sz pirt WM, Heaf JG, Petersen J. Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's granulomatosis: a clinical randomized controlled trial. Nephrol Dial Transplant 2011; 26:206-213.
11. Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoid dosing in the treatment of antineutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials 2013; 14:73. Although this trial is ongoing, we need to be alert for the outcome that will provide very important guidelines or recommendations regarding the role of plasmapheresis in severe or critical disease.
12. De Gr oot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-Associated vasculitis. Arthritis Rheum 2005; 52:2461-2469.
13. Langford CA, Talar-Williams C, Sneller MC. Use of methotrexate and gluco corticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 2000; 43: 1836-1840.
14. Hu W,Liu C,Xie H,et al. Mycopheno late mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement Nephrol Dial Transplant 2008 23 1307-1312.
15. Schonermarck U, Gross WL, de Groot K. Treatment of ANCA-Associated vasculitis. Nat Rev Nephrol 2014; 10:25-36.
16. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-Associated renal vasculitis. N Engl J Med 2010; 363:211-220.
17. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-Associated vasculitis. N Engl J Med 2010; 363:221-232.
18. Miloslavsky EM, Specks U, Merkel PA, et al. Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-Associated vasculitis. Arthritis Rheumatol 2014; 66:3151-3159. This study suggests that RTX is a well tolerated and effective treatment for relapses in adults with AAV.
19. Guerry MJ,Brogan P,Bruce IN,et al. Recommendations for the use of rituximab in antineutrophil cytoplasm ant ibody-Associated vasculitis Rheumatology (Oxford) 2012 51 634-643. These are the expert consensus recommendations for use of RTX in AAV, based on systematic review of the literature and consensus of expert rheumatologists, nephrolo gists, and a pediatrician.
20. Seror R, Pagnoux C, Ruivard M, et al. Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-li ne induction-refractory disease in the WEGENT trial. Ann Rheum Dis 2010; 69:2125-2130.
21. de Menthon M, Cohen P, Pagnoux C, et al. Infliximab or rituximab for refractory Wegener's granulomatosi s: long-term follow up. A prospective randomised multicentre study on 17 patients. Clin Exp Rheumatol 2011; 29 (Suppl 64):S63-S71.
22. Laurino S, Chaudhry A, Booth A, et al. Prospective study of TNFalpha blockade with adalimumab in ANCA-Associated systemic vasculitis with renal involvement. Nephrol Dial Transplant 2010; 25:3307-3314.
23. Langford CA, Monach PA, Specks U, et al. An open-label trial of abatacept (CTLA4-IG) in nonsevere relapsing granulomatosis with polyangiitis (Wegener's). Ann Rheum Dis 2014; 73:1376-1379.
24. Lenert A, Lenert P. Current and emerging treatment options for ANCAassociated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents. Drug Des Devel Ther 2015; 9:333-347.
25. Wegener's Granulomatosis Etanercept Trial (WGET) Research, Group. Etanercept plus standard therapy for Wegener's, granulomatosis. N Engl J Med 2005; 352:351-361.
26. Lapraik C, Watts R, Bacon P, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) 2007; 46:1615-1616.
27. Walsh M, Flossmann O, Berd en A, et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-Associated vasculitis. Arthritis Rheum 2012; 64:542-548.
28. Jayne D, Rasmussen N, Andrassy K, et al. A rand omized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36-44.
29. Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-Associated vasculitis. N Engl J Med 2008; 359:2790-2803.
30. Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs azathioprine for remission maintena nce in antineutrophil cytoplasmic antibody-Associated vasculitis: a randomized controlled trial. JAMA 2010; 304:2381-2388.
31. Metzler C, Miehle N, Manger K, et al. Elevated relapse rate under o ral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) 2007; 46:1087-1091.
32. Hazlewood GS, Metzler C, Tomlinson GA, et al. Nonbiologic re mission maintenance therapy in adult patients with ANCA-Associated vasculitis: a systematic review and network meta-Analysis. Joint Bone Spine 2014; 81:337-341.
33. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-Associated vasculitis. N Engl JMed 2014; 371:1771-1780. A clear role of RTX vs. other therapies in both remission induction and remission maintenance for AAV is still emergi ng. This randomized trial demonstrates superiority of RTX over AZA.
34. Stegeman CA, Tervaert JW, Sluiter WJ, et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener g ranulomatosis. Ann Intern Med 1994;120(1):12-17.
35. Roediger FC, Orloff LA, Courey MS. Adult subglottic stenosis: management with laser incisions and mitomycin-C. Laryngoscope 2008; 118:1542-1546.
36. Fowler NM, Beach JM, Krakovitz P, Spalding SJ. Airway manifestations in childhood granulomatosis with polyangiitis (Wegener's). Arthritis Care Res (Hoboken) 2012; 64:434-440. Upper airway manifestations, particularly upper airway stenoses, have been described as more characteristic of childhood GPA than adult disease. This pediatric study describes the extent, severity, and relative resistance to systemic therapy ; it describes the need for careful surveillance for this manifestation throughout the disease course, and it describes their strategies for treatment that include an emphasis on localized therapy.
37. Kerr GS, Hallahan CW, Gi ordano J, et al. Takayasu arteritis. Ann Intern Med 1994; 120:919-929.
38. Kotter I, Henes JC, Wagner AD, et al. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell ar teritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clin Exp Rheumatol 2012; 30 (Suppl 70):S114-S129.
39. Liang P, Hoffman GS. Advances in the medical and surgical treatment of Takayasu arteritis. Curr Opin Rheumatol 2005; 17:16-24.
40. Brunner J,Feldman BM,Tyrrell PN,et al. Takayasu arteritis in children and adolescents Rheumatology (Oxford) 2010 49 1806-1814.
41. Szugye HS, Zeft AS, Spalding SJ. Takayasu arteritis in the pediatric population: a contemporary United States-Based Single Center Cohort. Pediatr Rheumatol Online J 2014; 12:21. This article describes the largest US case series of pediatric TAK.
42. Ozen S, Duzova A, Bakkaloglu A, et al. Takayasu arteritis in children: preliminary experience with cyclophosphamide induction and corticosteroids followed by methotrexate. J Pediatr 2007; 150:72-76.
43. Stern S, Clemente G, Reiff A, et al. Treatment of pediatric Takayasu arteritis with infliximab and cyclophosphamide: experience from an American-Brazilian cohort stud y. J Clin Rheumatol 2014; 20:183-188. This retrospective analysis of 23 pediatric patients with TAK suggests that infliximab may be an effective alternative to cyclophosphamide in the treatment of TAK.
44. Buonu omo PS, Bracaglia C, Campana A, et al. Infliximab therapy in pediatric Takayasu's arteritis: report of two cases. Rheumatol Int 2011; 31:93-95.
45. Filocamo G, Buoncompagni A, Viola S, et al. Treatment of Takayasu's arteritis with tumor necrosis factor antagonists. J Pediatr 2008; 153:432-434.
46. Kaneko U, Kishi T, Kikuchi M, et al. Infliximab therapy for three adolesc ent patients with refractory Takayasu's arteritis. Nihon Rinsho Meneki Gakkai Kaishi 2010; 33:317-323.
47. El-Matary W, Persad R. Takayasu's aortitis and infliximab. J Pediatr 2009; 155:151.
48. Goel R, Kumar TS, Danda D, et al. Childhood-onset Takayasu arteritis: experience from a tertiary care center in South India. J Rheumatol 2014; 41:1183-1189.
49. Canas CA, Canas F, Izquierdo JH, et al. Efficacy and safety of antiinterleukin 6 receptor monoclonal antibody (tocilizumab) in Colombian patients with Takayasu arteritis. J Clin Rheumatol 2014; 20:125-129.
50. Bravo Mancheno B, Perin F, Guez Vazquez Del Rey Mdel M, et al. Successful tocilizumab treatment in a child with refractory Takayasu arteritis. Pediatrics 2012; 130:e1720-e1724.
51. Walters HM, Aguiar CL, Macdermott EJ, et al. Takayasu arteritis presenting in the context of active tuberculosis: a pediatric case. J Clin Rheumatol 2013; 19:344-347.
52. Liang P, Tan-Ong M, Hoffman GS. Takayasu's arteritis: vascular interventions and outcomes. J Rheumatol 2004; 31:102-106.
53. Mason JC. Takayasu arteritis: surgical interventions. Curr Opin Rheumatol 2015; 27:45-52.
54. de Souza AW, Machado NP, Pereira VM, et al. Antiplatelet therapy for the prevention of arterial ischemic events in takayasu arteritis. Circ J 2010; 74:1236-1241.
55. Chatterjee S, Flamm SD, Tan CD, Rodriguez ER. Clinical diagnosis and management of large vessel vasculitis: Takayasu arteritis. Curr Cardiol Rep 2014; 16:499.
56. Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 2006; 65:936-941.
57. Zhou Q, Y ang D, Ombrello AK, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med 2014; 370:911-920.
58. Navon Elkan P, Pierce SB, Segel R, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 2014; 370:921-931. This is an important study describing mutations in single gene that resulted in PAN, a disease generally considered polygenetic and/or mul tifactorial.
59. Ozen S, Anton J, Arisoy N, et al. Juvenile polyarteritis: results of a multicenter survey of 110 children. J Pediatr 2004; 145:517-522.
60. Eleftheriou D, Dillon MJ, Tullus K, et al. Systemic polyarteritis nodosa in the young: a single-center experience over thirty-two years. Arthritis Rheum 2013; 65:2476-2485. This is the largest single-center series describing the clinical features, treatment, and outcome of systemic childhood PAN.
61. Dillon MJ, Eleftheriou D, Brogan PA. Medium-size-vessel vasculitis. Pediatr Nephrol 2010; 25:1641-1652.
62. . Mondal R, Sarkar S, Pal P, et al. Childhood polyarteritis nodosa: a prospective multicentre study from eastern India. Indian J Pediatr 2014; 81:371-374.
63. Wright E, Dillon MJ, Tu llus K. Childhood vasculitis and plasma exchange. Eur J Pediatr 2007; 166:145-151.
64. Eleftheriou D, Melo M, Marks SD, et al. Biologic therapy in primary systemic vasculitis of the young. Rheumatology (Oxford) 2009; 48:978-986.
65. Campanilho-Marques R,Ramos F,Canhao H,Fonseca JE. Remission induced by infliximab in a childhood polyarteritis nodosa refractory to conventional immu nosuppression and rituximab Joint Bone Spine 2014 81 277-278.
66. Fernanda F, Serena C, Giustina R, et al. Mycophenolate mofetil treatment in two children with severe polyarteritis nodosa refr actory to immunosuppressant drugs. Rheumatol Int 2012; 32:2215-2219.
67. Bansal NK, Houghton KM. Cutaneous polyarteritis nodosa in childhood: a case report and review of the literature. Arthritis 2010; 2010:687547.
68. Haviv R, Capua M, Amir J, Harel L. Cutaneous polyarteritis nodosa successfully treated with topical diflucortolone valerate: a case report & review of the literature. P ediatr Rheumatol Online J 2014; 12:46.
69. Till SH, Amos RS. Long-term follow-up of juvenile-onset cutaneous polyarteritis nodosa associated with streptococcal infection. Br J Rheumatol 1997; 36:909-911.
70. Tonnelier JM, Ansart S, Till y-Gentric A, Pennec YL. Juvenile relapsing periarteritis nodosa and streptococcal infection. Joint Bone Spine 2000; 67:346-348.
71. van Montfrans J, Zavialov A, Zhou Q. Mutant ADA2 in vasculopathies. N Engl J Med 2014; 371:478.
72. Van Eyck L, Liston A, Meyts I. Mutant ADA2 in vasculopathies. N Engl J Med 2014; 371:478-479.
73. Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994; 87:671-678.
74. Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009; 68:1827-1832.
75. de Groot K, Gross WL, Herlyn K, Reinhold-Keller E. Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol 2001; 55:31-38.
76. Exley AR, Bacon PA, Luqmani RA, et al. Development and initial validation of the vasculitis damage index for th e standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997; 40:371-380.
77. Wilkinson NM, Page J, Uribe AG, et al. Establishment of a pilot pediatric registry for chronic vasculitis is both essential and feasible: a Childhood Arthritis and Rheumatology Alliance (CARRA) survey. J Rheumatol 2007; 34:224-226.
78. Dolezalova P, Price-Kuehne FE, Ozen S, et al. Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS). Ann Rheum Dis 2013; 72:1628-1633.